<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279175</url>
  </required_header>
  <id_info>
    <org_study_id>2/04</org_study_id>
    <secondary_id>Paul-Ehrlich-Institute 1034/01</secondary_id>
    <secondary_id>EudraCT 2006-000250-43</secondary_id>
    <nct_id>NCT00279175</nct_id>
  </id_info>
  <brief_title>REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)</brief_title>
  <official_title>Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR - AMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A. M. Zeiher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blutspendedienst Baden-Württemberg - Hessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guidant Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      Impaired contractile function after a heart attack of the heart is a major cause of &quot;heart
      failure&quot; limiting quality of life and prognosis, which cannot be prevented even with optimal
      standard therapy, including immediate balloon/stent dilation of the infarct vessel.

      The aim of the REPAIR-AMI trial is to investigate whether infusion of progenitor cells into
      the infarct vessel (after successful reperfusion therapy) may improve left ventricular
      contractile function compared to placebo therapy. After bone marrow aspiration progenitor
      cells are enriched via a centrifugation method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The study is a double-blind, placebo-controlled, randomized, multicenter trial.

        -  Patients after an acute myocardial infarction, undergoing successful reperfusion therapy
           are included.

        -  All patients undergo bone marrow aspiration 3 to 6 days after the infarction.

        -  After cell processing, enriched bone marrow-derived progenitor cells or placebo medium
           is infused direct into the infarct related artery during stop-flow. In addition, a left
           ventricular angiography is performed.

        -  After 4 months left ventricular angiography is repeated. The primary endpoint is the
           difference in change of left ventricular ejection fraction between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global left ventricular function in quantitative LV angiography after 4 months.</measure>
    <time_frame>baseline to 4 months</time_frame>
    <description>absolute delta LVEF (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary endpoint in patients without restenosis.</measure>
    <time_frame>baseline to 4 months</time_frame>
    <description>absolute delta LVEF (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of regional wall motion in infarct area</measure>
    <time_frame>baseline to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of LV end-systolic volume</measure>
    <time_frame>baseline to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>at 4, 12 and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization due to heart failure.</measure>
    <time_frame>4, 12, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA status after 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amendment for extended follow up after 2 and 5 years:</measure>
    <time_frame>24 and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>outcomes in major adverse cardiac events (MACE)</measure>
    <time_frame>4, 12, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization due to heart failure</measure>
    <time_frame>4, 12, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA status</measure>
    <time_frame>4, 12, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients in MRI subgroup: improvement in left ventricular function</measure>
    <time_frame>4, 12, 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>BMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary infusion of autologous bone marrow derived cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intracoronary infusion of Placebo medium</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intracoronary infusion of enriched bone marrow-derived progenitor cells</intervention_name>
    <arm_group_label>BMC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo medium supplemented with autologous serum</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute myocardial infarction (ST elevation in at least 2 leads &gt;= 0.2 mV
             in V1,V2 or V3 or &gt;= 0.1 mV in other leads), treated by one of the following
             procedures

               -  Either acute PCI with stent implantation within 24 hours after symptom onset or

               -  treatment with thrombolysis within 12 hours of symptom onset followed by PCI with
                  stent implantation within 24 hours after thrombolysis.

          -  Acute PCI / stent implantation has been successful (residual stenosis visually &lt; 30%
             and TIMI flow &gt;= 2).

          -  At the time of inclusion patient does no longer require i.v. catecholamines or
             mechanical hemodynamic support (aortic balloon pump)

          -  Significant regional wall motion abnormality in LV angiogram at the time of acute PCI
             (ejection fraction &lt;= 45% on visual estimation).

          -  Maximal CK elevation &gt;= 400 U/l (measured at 37° C) with significant MB fraction &gt; 6%

          -  Age 18 - 80 Years

          -  Written informed consent

        Exclusion Criteria:

          -  Regional wall motion abnormality outside the area involved in the index acute
             myocardial infarction.

          -  Need to revascularize additional vessels, outside the infarct artery.

          -  Arteriovenous malformations or aneurysms

          -  Active infection (CRP &gt; 10 mg/dl) now, or fever or diarrhea within last 4 weeks.

          -  Chronic inflammatory disease

          -  HIV infection or active hepatitis

          -  Neoplastic disease without documented remission within the past 5 years.

          -  Cerebrovascular insult within 3 months

          -  Impaired renal function (creatinine &gt; 2 mg/dl) at the time of cell therapy

          -  Significant liver disease (GOT &gt; 2x upper limit) or spontaneous INR &gt; 1,5)

          -  Anemia (hemoglobin &lt; 8.5 mg/dl)

          -  Platelet count &lt; 100.000/µl

          -  Hypersplenism

          -  Known allergy or intolerance to clopidogrel, heparin or abciximab.

          -  History of bleeding disorder

          -  Gastrointestinal bleeding within 3 months

          -  Major surgical procedure or traumata within 2 months

          -  Uncontrolled hypertension

          -  Pregnancy

          -  Mental retardation

          -  Previously performed stem / progenitor cell therapy

          -  Participation in another clinical trial within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Zeiher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J. W. Goethe University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker Schächinger, MD</last_name>
    <role>Study Director</role>
    <affiliation>J. W. Goethe University Hopspitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG Kliniken Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotes-Kreuz Krankenhaus - Kardiologisches Centrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60316</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. W. Goethe University Hospitals</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parxis Schofer, Mathey und Partner</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklikum Homburg</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum - Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Suhl</name>
      <address>
        <city>Suhl</city>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Schächinger V, Tonn T, Dimmeler S, Zeiher AM. Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. Nat Clin Pract Cardiovasc Med. 2006 Mar;3 Suppl 1:S23-8.</citation>
    <PMID>16501626</PMID>
  </reference>
  <results_reference>
    <citation>Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1210-21.</citation>
    <PMID>16990384</PMID>
  </results_reference>
  <results_reference>
    <citation>Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006 Dec;27(23):2775-83. Epub 2006 Nov 10.</citation>
    <PMID>17098754</PMID>
  </results_reference>
  <results_reference>
    <citation>Dill T, Schächinger V, Rolf A, Möllmann S, Thiele H, Tillmanns H, Assmus B, Dimmeler S, Zeiher AM, Hamm C. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J. 2009 Mar;157(3):541-7. doi: 10.1016/j.ahj.2008.11.011. Epub 2009 Jan 31.</citation>
    <PMID>19249426</PMID>
  </results_reference>
  <results_reference>
    <citation>Erbs S, Linke A, Schächinger V, Assmus B, Thiele H, Diederich KW, Hoffmann C, Dimmeler S, Tonn T, Hambrecht R, Zeiher AM, Schuler G. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation. 2007 Jul 24;116(4):366-74. Epub 2007 Jul 9.</citation>
    <PMID>17620510</PMID>
  </results_reference>
  <results_reference>
    <citation>Assmus B, Rolf A, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Tillmanns H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Tonn T, Dimmeler S, Dill T, Zeiher AM, Schächinger V; REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010 Jan;3(1):89-96. doi: 10.1161/CIRCHEARTFAILURE.108.843243. Epub 2009 Dec 8.</citation>
    <PMID>19996415</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2006</study_first_submitted>
  <study_first_submitted_qc>January 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2006</study_first_posted>
  <last_update_submitted>September 19, 2012</last_update_submitted>
  <last_update_submitted_qc>September 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>A. M. Zeiher</investigator_full_name>
    <investigator_title>Professor Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

